bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + prednisone + dacarbazine

bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + prednisone + dacarbazine is an intensive multi‑agent chemotherapy regimen used primarily for advanced classical Hodgkin lymphoma as a modification of escalated BEACOPP, in which dacarbazine replaces procarbazine to reduce toxicity while aiming to preserve efficacy.[4] It combines several small‑molecule cytotoxics with complementary mechanisms: bleomycin causes DNA strand breaks via free radical formation; etoposide inhibits topoisomerase II–mediated DNA relegation; doxorubicin intercalates DNA and inhibits topoisomerase II with associated free radical damage; cyclophosphamide and dacarbazine are alkylating agents that form DNA crosslinks; vincristine is a vinca alkaloid that disrupts microtubule assembly and mitotic spindle function; and prednisone is a glucocorticoid inducing apoptosis in lymphoid cells and providing anti‑inflammatory and antiemetic benefits.[1][2][4][6] This regimen is typically administered in 21‑day cycles with most cytotoxics given intravenously and prednisone given orally, often with prophylactic granulocyte colony‑stimulating factor because of its myelosuppressive intensity.[4][6]

Other names

BEACOPDacBEACOPDac escalated dose